» Articles » PMID: 23817321

Epidemiology and Natural History of HCV Infection

Overview
Specialty Gastroenterology
Date 2013 Jul 3
PMID 23817321
Citations 388
Authors
Affiliations
Soon will be listed here.
Abstract

Worldwide, an estimated 130-170 million people have HCV infection. HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million). Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries. Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades. Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations. Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favourable IL28B genotypes, acute symptoms and in women. The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC. Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alcohol intake and HIV co-infection.

Citing Articles

Detection of Hepatitis C Virus Infection from Patient Sera in Cell Culture Using Semi-Automated Image Analysis.

Schafer N, Rothhaar P, Heuss C, Neumann-Haefelin C, Thimme R, Dietz J Viruses. 2025; 16(12.

PMID: 39772180 PMC: 11680372. DOI: 10.3390/v16121871.


Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention Strategies.

Cheema J, Suckow S, Ramers C, Loose P, Tomada A, Tweeten S Viruses. 2025; 16(12.

PMID: 39772129 PMC: 11680419. DOI: 10.3390/v16121819.


Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study.

Chen Y, Bao Y, Yan M, Jin H, Yao K, Zhang C Infect Dis Ther. 2024; 14(1):181-197.

PMID: 39663286 PMC: 11782747. DOI: 10.1007/s40121-024-01084-0.


A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study.

Marshall A, Conway A, Cunningham E, Valerio H, Silk D, Alavi M Viruses. 2024; 16(11).

PMID: 39599877 PMC: 11599082. DOI: 10.3390/v16111763.


The Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma.

Cardoso M, Verdelho Machado M Cancers (Basel). 2024; 16(22).

PMID: 39594679 PMC: 11591730. DOI: 10.3390/cancers16223723.


References
1.
Tanaka Y, Hanada K, Orito E, Akahane Y, Chayama K, Yoshizawa H . Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol. 2005; 42(1):47-53. DOI: 10.1016/j.jhep.2004.09.023. View

2.
Alter M . Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17):2436-41. PMC: 4146761. DOI: 10.3748/wjg.v13.i17.2436. View

3.
Antaki N, Haddad M, Kebbewar K, Abdelwahab J, Hamed O, Aaraj R . The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect. 2008; 137(1):79-84. DOI: 10.1017/S095026880800054X. View

4.
Hui J, Sud A, Farrell G, Bandara P, Byth K, Kench J . Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2004; 125(6):1695-704. DOI: 10.1053/j.gastro.2003.08.032. View

5.
Deuffic-Burban S, Mathurin P, Valleron A . Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res. 2008; 18(3):233-52. DOI: 10.1177/0962280208094697. View